Fritextsökning
Artiklar per år
Innehållstyper
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
Ny miljonsatsning på life science i Sverige
7,7 miljoner kronor ska nu satsas på ett projekt för att underlätta identifiering och produktion av läkemedel. Bridge Sweden är namnet på projektet och är ett samarbete mellan olika aktörer i Sverige inom life science.
-
Han är ny på AAX Biotech
Startup-bolaget AAX Biotech har rekryterat Juan Astorga-Wells till tjänsten som Senior Manager of Science & Development.
-
Hon blir ny medicinsk chef på Synact Pharma
Synact Pharma, som bland annat utvecklar behandlingar för reumatiska sjukdomar, har utsett Kirsten Harting till ny Chief Medical Officer.
-
Han är ny på Capitainer
Solnaföretaget Capitainer har anställt Johan Olausson som applikationsspecialist.
-
”Information security must become part of the Swedish life science strategy”
Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.
-
Ingrid Lönnstedt: What does the p-value mean?
The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significance level. But what does that mean? Read Ingrid Lönnstedt´s column to learn more.
-
A vaccine the world is waiting for: “It can change the lives of many”
Manager.
-
The Swedish innovation model: “There is a paradox”
It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?
-
Ny chef på Key2compliance: “Lite mindre konventionell”
Affärsutvecklaren och projektledaren Jeanette Demorney blir ny affärsområdeschef för clinical development på Key2compliance.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
have since been a constant feature of her working life. Today, she is a Healthcare Manager in Microsoft’s Western Europe team.
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless different assignments later, Per Alfredsson, born and raised in Södertälje, is CEO of Astra Zeneca Sweden, which employs 7800 people in Södertälje, Stockholm and Gothenburg. “It was a very special feeling to be in charge of the entire organisation,” he says in an interview about his career and potential future blockbusters.
-
Samarbeten mellan stora svenska och nederländska aktörer förlängs
För ett år sedan tecknades fyra överenskommelser mellan svenska och nederländska aktörer inom life science. Nu förlängs samarbetena.
-
Ny vd för AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals har utsett Sofia Opitz till ny vd. Hon kommer närmast från en tjänst som Country Manager för Sverige, Norge och Danmark på företaget Biocodex.
-
Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell
Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Michael Linnell, project manager for Life Science Sweden’s event portfolio, a few short questions.
-
Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president
In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According to the reporter Theo Baker, who first reported the story, Tessier-Lavigne “rewarded the winners and punished the losers”. Here is the background of the story which has shaken the American scientific community over the summer.
-
AstraZeneca moves to brewery quarters in central Copenhagen
AstraZeneca in Denmark is moving its business into central Copenhagen and the old brewery quarters in Carlsberg Byen.
-
Rapid developments in AI – “All stakeholders are struggling to understand it”
Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, keeping up with developments is not easy.
-
15 framtidsyrken inom life science: “Huggsexa om kompetens”
Arbetsmarknaden för naturvetare som jobbar med life science har mycket goda framtidsutsikter. Det visar en ny rapport från fackförbundet Naturvetarna.
-
Uncertainty about the government’s life science work
The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now questions are being raised both about the government’s plans for the office and the Swedish life science strategy.
-
New diagnostic rules raise concerns
In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagnostics (IVDR). They argue that it may create significant differences between regions, and patients may be affected.
-
Hon ska ansvara för Gedeas kvalitetssäkring
Lundabolaget Gedea Biotech har utsett Anna-Karin Areskog till ny QA Director.
-
Kristdemokraterna rekryterar från Sanofi
Jonas Sareld, Public Affairs Manager vid Sanofi, blir kanslichef för Kristdemokraterna i Region Stockholm.
-
Meeting with focus on South Korea and Japan’s life sciences
Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage during a webcast seminar.
BREAKING